Brief: Inflarx Announces Positive Topline Results From The Single Ascending Dose (Sad) Phase I Study With C5ar Inhibitor Inf904
11/09/2023 12:27
InflaRx NV IF0G.F :
* INFLARX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE SINGLE
ASCENDING DOSE (SAD) PHASE I STUDY WITH C5AR INHIBITOR INF904
* INFLARX NV - SAFETY AND TOLERABILITY WITH NO SIGNALS OF
CONCERN
OVER ENTIRE DOSE RANGE
* INFLARX NV - MAD PART OF PHASE 1 TRIAL IS ONGOING, AND
COMPANY
EXPECTS TO PRESENT RESULTS FROM ABOUT 24 HEALTHY VOLUNTEERS AT
BEGINNING OF 2024
Source text for Eikon: ID:nGNX6mfkDq
Further company coverage: IF0G.F
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum